Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TELA Bio (TELA) Shares Outstanding (Weighted Average) (2018 - 2025)

TELA Bio (TELA) has 8 years of Shares Outstanding (Weighted Average) data on record, last reported at $45.4 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 83.58% year-over-year to $45.4 million; the TTM value through Sep 2025 reached $45.4 million, up 83.58%, while the annual FY2024 figure was $28.5 million, 24.74% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $45.4 million in Q3 2025 per TELA's latest filing, roughly flat from $45.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $45.4 million in Q3 2025 and bottomed at $14.4 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $23.5 million, with a median of $22.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 0.27% in 2021, then soared 84.17% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $14.5 million in 2021, then grew by 12.4% to $16.3 million in 2022, then surged by 40.58% to $22.9 million in 2023, then increased by 24.74% to $28.5 million in 2024, then surged by 58.98% to $45.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $45.4 million in Q3 2025, $45.3 million in Q2 2025, and $45.3 million in Q1 2025.